Table 2 Demographic data and AT(N) cerebrospinal fluid biomarker profiles of all included patients, divided according to their clinical syndrome
Normal^ (n = 132) | AD-continuum^ (n = 389) | Non-AD^ (n = 107) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
n | Age* | M:F | A−T−(N−) | A+T−(N−) AD pathologic change | A+T+(N−) AD | A+T+(N+) AD | A+T−(N+) AD and non-AD pathologic change | A−T+(N−) | A−T−(N+) | A−T+(N+) | |
AD | 229 | 72 ± 8 | 96:133 | 1 (0.4) | 56 (24.5) | 34 (14.9) | 118 (51.6) | 7 (3.1) | 5 (2.1) | 1 (0.4) | 7 (3.0) |
FTD | 107 | 73 ± 7 | 61:46 | 39 (36.5) | 11 (10.4) | 7 (6.5) | 9 (8.4) | 1 (0.9) | 15 (14.0) | 4 (3.7) | 21 (19.6) |
LBD | 37 | 76 ± 5 | 20:17 | 13 (35.1) | 9 (24.3) | 4 (10.8) | 3 (8.1) | 2 (5.4) | 2 (5.4) | 1 (2.7) | 3 (8.1) |
PSP/CBS | 12 | 69 ± 7 | 6:6 | 9 (75.0) | 1 (8.3) | – | 2 (16.7) | – | – | – | – |
PD | 5 | 62 ± 18 | 2:3 | 4 (80.0) | 1 (20%) | – | – | – | – | – | – |
VaD/mixed | 67 | 76 ± 6 | 37:30 | 17 (25.4) | 16 (23.9) | 6 (8.9) | 8 (11.9) | – | 10 (14.9) | – | 10 (14.9) |
Others° | 30 | – | – | 15 (50.0) | 7 (23.3) | 1 (3.3) | 2 (6.7) | – | 1 (3.3) | 1 (3.3) | 3 (10.0) |
MCI | 132 | 73 ± 7 | 62:70 | 27 (20.4) | 35 (26.5) | 18 (13.6) | 25 (18.9) | 4 (3.0) | 11 (8.3) | – | 12 (9.2) |
CU | 9 | 69 ± 6 | 8:1 | 7 (77.8) | 2 (22.2) | – | – | – | – | – | – |
Total | 628 | 132 (21.0) | 138 (22.0) | 70 (11.1) | 167 (26.6) | 14 (2.2) | 44 (7.0) | 7 (1.1) | 56 (9.0) | ||